medicine
Medicine
Biologics are a special type of powerful drugs such as recombinant proteins, microorganisms, cells and other biological products obtained by the application of genetic engineering, cell engineering, protein engineering, fermentation engineering and other biotechnologies. Biologics, especially antibody drugs as an effective treatment approach, has been developed rapidly in recent years. It brings hope to more patients with better efficacy and less side effects for many common diseases including cancer. It can also significantly improve patients' survival rate and quality of life.
Focusing on innovative biologics R&D, mainly antibody therapeutics, we have constructed three support systems, built up four departments and five core technology platforms to support the whole process of biologics R&D from discovery to IND filing.
We are committed to develop safe and highly effective biologics to meet major unmet medical needs by focusing on oncology, respiratory diseases, kidney illnesses and infectious diseases.
We have established a complete R&D system and advanced technical platforms from discovery, process development and manufacturing, pre-clinical study to clinic trial to allow development of various biologics such as monoclonal antibodies, bi-specific antibodies, and fusion proteins.
| Pipeline | S/N | Product number | Product introduction |
|---|---|---|---|
| Kidney Diseases |
1 | JYB1931 | With the advantages of clear mechanism and high specificity, it has entered the clinical stage |
| Oncology | 2 | JYB1907 | Targeting multiple solid tumors, with significant in vivo efficacy and low toxicity, has entered the clinical stage |
| 3 | JMB2003 | Dual antibody products simultaneously target tumors and tumor microenvironment, with overlapping anti-tumor effects and significant preclinical effects | |
| Respiratory Diseases | 4 | JYB1904 | The half-life is significantly extended compared to similar products, making it convenient to apply and meeting the needs of treatment compliance |
| 5 | JMB2004 | Affinity and positive animal efficacy results fill the clinical treatment gap |
The Innovative Biologics Research Institute has a team of 60 scientists, of whom 11% hold PhD degree and 56% hold MS degree. The top management team consists of scientists with more than 20 years of oversea Biopharma and Biotech industrial experiences.
Based on our high quality human naive antibody library, the technologies of phage antibody display and yeast antibody display are integrated into a platform named as PtY (Phage-to-Yeast) antibody discovery platform. It has the unique advantages of high throughput from phage display and real-time visualization and multi-dimensional screening from yeast display. In practice, it can rapidly and precisely screen out antibody candidates that recognize unique epitopes for drug targets and greatly shorten the timeline of antibody discovery.
Nanchang National High-tech Industrial
Development Zone, Jiangxi Province,
China No. 3333, West Yaohu Avenue
Tel:0791-87339727
Fex:0791-87339712
Email:service@jemincare.com(PR)
